10 research outputs found
Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss
Differences in hormone receptor and HER-2 status between primary tumour and corresponding relapse could have a substantial impact on clinical management of patients. The aim of this study was to evaluate change in expression of hormone receptors and HER-2 status between primary tumour and corresponding local recurrence or distant metastasis. We analysed 140 primary tumours and related recurrent or metastatic samples. Hormone receptors status was evaluated by immunohistochemistry, while HER-2 status by immunohistochemistry and silver in situ hybridisation. A change in HER-2 was rare; 3.7% of cases by immunohistochemistry and only 0.7% by silver in situ hybridisation analysis. A change in estrogen and progesterone receptors was seen in 6.4% and 21.4% of cases, respectively. Estrogen receptor change was not affected by adjuvant therapy, whereas progesterone receptor was influenced by adjuvant chemotherapy associated to hormone therapy (P = 0.0005). A change in progesterone receptor was more frequent in distant metastases than in local recurrences (P = 0.03). In the setting of estrogen receptor positive tumours, patients with progesterone receptor loss in local recurrence had a statistically significant lower median metastasis free survival compared to others patients; progesterone receptor positive, 112 months; progesterone receptor negative, 24 months (P = 0.005). A change between primary tumour and corresponding relapse is frequent for progesterone receptor, infrequent for estrogen receptor and rare for HER-2. In cases with changes in HER-2, it is worthwhile reassessing HER-2 status with both immunohistochemistry and in situ hybridisation analysis. Progesterone receptor loss seems to be influenced by therapy and to correlate with a worse prognosis
Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients
When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer?
Small (pT1a-b), node-negative (pN0) breast cancer generally has a good prognosis. However, HER2-positive status is associated with an increased risk of relapse and decreased survival even in these tumors. Although there are only few data from prospective randomized trials, results of retrospective studies suggest adjuvant chemotherapy plus trastuzumab may improve outcomes of patients with pT1a-b pN0 HER2-positive breast cancer. On the other hand, trastuzumab is potentially associated with increased cardiac toxicity, especially when combined with anthracycline-based chemotherapy. A valid strategy for improving cardiac safety is the addition of trastuzumab to non-anthracycline chemotherapy, whereas a shorter duration of trastuzumab should be not routinely considered although might represent an option for selected patients at low risk of relapse and very high risk of cardiac events. Therefore, the choice of adjuvant treatment for patients with pT1a-b pN0 HER2-positive breast cancer should be done on individual basis, carefully weighing benefits and risks
Neuroendocrine carcinoma of the breast: Current evidence and future perspectives
: Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline- and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast
Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome
AIMS:
Primary neuroendocrine (NE) breast carcinoma (BC) is an entity with a wide range of prevalence and poorly defined clinical behavior. We evaluated the prevalence, clinicopathological features and clinical outcome of NEBC.
METHODS AND RESULTS:
Immunohistochemical staining for synaptophysin and chromogranin A was performed on whole sections from 1232 consecutive cases of invasive BC. We divided NEBC in focal (10-49% positive cells) and diffuse ( 6550% positive cells) and compared the outcome of patients with NEBC with strictly matched non-NEBC. A total of 128 BC showed NE differentiation (10.4%): 84 diffuse (6.8%) and 44 focal (3.6%). NE differentiation showed a significant association with T4 stage (P=0.001), solid-papillary and mucinous histotype (P<0.0001), G2 grading (P=0.002), positive ER (P=0.003) and PR (P=0.002). Almost 90% of NEBC are ER+/HER2- and more than half ER+/HER2-/Ki-67 6514%. Kaplan-Meier analysis revealed that patients with NEBC showed worse disease-free survival (DFS) (P=0.04) compared to matched non-NEBC. We did not find significant differences regarding clinicopathological features, DFS and CSS between diffuse and focal neuroendocrine BC CONCLUSIONS: This study demonstrates that NEBC represents 7-10% of invasive BC and that NE differentiation does not affect the prognosis of BC in terms of CSS. This article is protected by copyright. All rights reserved
Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities
To evaluate the differences between conventional fractionated intensity-modulated radiotherapy (IMRT) and hypofractionated (HypoRT) volumetric modulated arc therapy (VMAT) in elderly women affected by early-stage breast cancer (BC) in terms of RT-related acute/late side effect
P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas
Triple-negative breast carcinomas represent a tumor group of pivotal clinical importance given the lack of target
therapies. The prognostic significance of triple-negative breast carcinomas remains unclear because of their
histological and molecular heterogeneity. Currently, neither prognostic nor predictive factors are available for
these tumors. Retinoblastoma (Rb) pathway loss has been linked to clinical outcome in various cancer types,
including breast cancer. We investigated the association between Rb and p16 protein expression and clinical
outcome in no-special-type triple-negative breast carcinomas. Immunohistochemical staining for Rb, p16, p53
and CK5 was carried out on a section from archival specimens of 117 no-special-type triple-negative breast
carcinomas. Immunopositive p16 (p16\ufe) and immunonegative Rb (Rb) staining were seen in 49.5% and
in 24.8% of tumors, respectively. There was an inverse correlation between p16\ufe and Rb (Po0.001). P16\ufe
was correlated with G3 grade (Po0.001), high Ki-67 (P\ubc0.03), p53 overexpression (Po0.001) and CK5
immunopositivity (P\ubc0.01). Rb was not associated with any clinicopathologic variable. Follow-up and
therapy data were available in 95 patients. In 20 patients treated with surgery only, neither p16\ufe nor Rb
immunostaining were associated with disease-free survival and overall survival. In 75 patients treated with
adjuvant chemotherapy, p16\ufe was associated with good response to therapy with significant increased
disease-free survival (P\ubc0.001) and showed a trend towards a statistical significance for increased overall
survival (P\ubc0.056); Rb were not associated with disease-free survival and overall survival. In multivariate
analysis, p16\ufe was independently associated with disease-free and overall survival, with a hazard ratio of 0.18
(95% CI: 0.06\u20130.51; P\ubc0.001) and 0.21 (95% CI: 0.06\u20130.74; P\ubc0.015), respectively. In patients with no-specialtype
triple-negative breast carcinomas, p16\ufe is related to good response to adjuvant chemotherapy and can be
considered the best surrogate marker for Rb pathway loss.
Modern Pathology advance online publication, 26 July 2013; doi:10.1038/modpathol.2013.13
DataSheet_1_The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy.pdf
IntroductionThe role of fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in early breast cancer treated with preoperative systemic therapy (PST) is not yet established in clinical practice. PET parameters have aroused great interest in the recent years, as non-invasive dynamic biological markers for predicting response to PST.MethodsIn this retrospective study, we included 141 patients with stage II-III breast cancer who underwent surgery after PST. Using ROC analysis, we set optimal cutoff of FDG-PET/CT parameters predictive for pathological complete response (pCR). We investigated the correlation between FDG-PET/CT parameters and pCR, median disease-free survival (DFS), and median overall survival (mOS).ResultsAt multivariable analysis, baseline SUVmax (high vs low: OR 9.00, CI 1.85 – 61.9, p=0.012) and Delta SUVmax (high vs low: OR 9.64, CI 1.84, 69.2, p=0.012) were significantly associated with pCR rates. Interestingly, we found that a combined analysis of the metabolic parameter Delta SUVmax with the volume-based parameter Delta MTV, may help to identify patients with pCR, especially in the subgroup of hormone receptor positive breast cancer. Delta SUVmax was also an independent predictive marker for both mDFS (high vs low: HR 0.17, 95%CI 0.05-0.58, p=0.004) and mOS (high vs. low: HR 0.19, 95%CI 0.04-0.95, p=0.029).DiscussionOur results suggest that Delta SUVmax may predict survival of early BC patients treated with PST.</p
Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities
Oncoplastic and reconstructive surgery in SENONETWORK Italian breast centers: lights and shadows
: • Despite the significance of oncoplastic procedure, an italian database is lacking. • Senonetwork established a multidisciplinary survey to assess their safety and efficacy. • Reconstructive outcomes were positive across low and high-volume centers. • After mastectomy, implant-based techniques are common. DTI reconstruction is advantageuos. • This contributes to the global understanding of effective strategies against breast cancer